| abstract |
A compound of formula I, ** (See formula) ** wherein A is a five-membered unsaturated heterocyclic ring containing 1, 2, or 3 ring heteroatoms, each independently selected from N, O, and S, in that said heterocyclic ring is unsubstituted or said heterocyclic ring is substituted with 1 substituent R1, or said heterocyclic ring is substituted with 2 substituents R1 and R2, or said heterocyclic ring is substituted with 3 substituents R1, R2 and R3, or said ring heterocyclic is substituted with 4 substituents R1, R2, R3 and R4; R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) hydroxyalkyl, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C6) alkoxy - (C = O) -, CN, (C1-C6) alkyl - (C = O) -, R5R6N-, R5R6N- (C = O) -, R6 (C = O) -R5N-, heterocyclyl, heterocyclyl-N- or phenyl-N-, wherein said heterocyclyl or phenyl is optionally substituted with 1, 2, 3 or 4 substituents, each independently selected from (C1-C6) alkyl, (C1-C6) alkoxy, oxo or phenylalkoxy (C1-C6); R2 is (C1-C6) alkyl, (C1-C6) alkoxy or (C1-C6) alkoxy (C1-C6) alkyl; R3 is (C1-C6) alkyl, (C1-C6) alkoxy or (C1-C6) alkoxy (C1-C6) alkyl; R4 is (C1-C6) alkyl; R5 is H or (C1-C6) alkyl; and R6 is H or (C1-C6) alkyl; or R1 and R2 form, together with the ring atoms to which they are attached, a 6-membered fused heterocyclic ring, containing 1 or 2 heteroatoms that are N; or a pharmaceutically acceptable salt or ester thereof; provided that A is not 1,2,3-oxadiazol-3-io-3-yl. |